Company intelligence / Profile preview

RemAb Therapeutics

Hospitalet de Llobregat / Barcelona area, Catalonia, Spainremabtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

RemAb’s lead candidate RA-01/RA‑0127 targets Gram-negative bacterial infections and has completed preclinical regulatory studies with a first-in-human trial design validated by Spanish regulators. The technology offers immediate action without generating antimicrobial resistance and can be synthetically produced with an excellent safety profile. Several additional programs are at the preclinical stage targeting hematologic and immune system diseases.

Therapeutic areas: HematologyImmunologyInfectious Diseases
Modalities: polymeric glycoconjugatessynthetic polymeric conjugatesdrug conjugates
Industry: Biotech

Drug pipeline

5 assets

RA0127

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on RemAb Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RemAb Therapeutics.

Explore the full profile